SunAct Partners with Abgentil to Introduce CAR-T, TCR, and TIL therapies in India, ET HealthWorld
Mumbai: SunAct Cancer Institute has signed an agreement with Malaysia-based Abgentil Biomedical SDN BHD to introduce CAR-T, TCR, and TIL therapies for solid tumors in India.
“Research indicates that most cancers diagnosed in the country are solid tumors, including head, neck, breast, and lung cancers. Tragically, many patients present with these cancers at advanced stages, where even surgery, radiation, chemotherapy, targeted therapy, and immunotherapy often fail to yield results,” said Dr. Vijay Patil, founder, SunAct.
“Alternative and innovative treatment options, such as adoptive cellular therapies like CAR-T, TCR, and TIL, represent a beacon of hope. TIL therapy has received FDA approval for melanoma and has shown impressive efficacy, while TCR therapies have recently been authorized for sarcoma treatment. Despite this, access to these adoptive therapies remains a significant challenge in India,” Dr. Patil added.
According to the release, by the end of next year, the Mumbai-based cancer institute plans to open its first facility in Khar/Bandra (Mumbai). Over the next five years, additional centers are planned in Pune, Delhi/NCR, Bangalore, and other major metropolitan cities.
Visit: Valley Vision News
